Precise MRD
Minimal Residual Disease monitoring
Development/CommercialActive
Key Facts
Indication
Minimal Residual Disease monitoring
Phase
Development/Commercial
Status
Active
Company
About Myriad Genetics
Myriad Genetics is a leading, publicly-traded precision medicine company focused on molecular diagnostics. Founded in 1991, it pioneered hereditary cancer testing with its BRACAnalysis test and has since built a diversified portfolio across five key therapeutic areas. The company's strategy centers on leveraging its large-scale genetic database and integrated germline/tumor profiling platform to deliver clear, actionable results that guide clinical decisions. Under new leadership, Myriad is focused on operational excellence, commercial execution, and strategic innovation to drive growth.
View full company profile